CD19 CART-cell therapy (GLPG5101) for relapsed or refractory B-cell non-Hodgkin lymphoma (ATALANTA-1) : phase 1 results from a single-arm, multicentre, phase 1/2 study

Source
Lancet haematology - ISSN 2352-3026-13:9 (2026) p. 648-659
Author(s)
    Marie Jose Kersten, Maria T. Kuipers, Pim G.N.J. Mutsaers, Evelyne Willems, Kirsten Saevels, Martin Dreyling, Caron Jacobson, Michael R. Bishop, Maarten Zandvliet, Stavros Milatos, Chiara Lobetti-Bodoni, Sandra Blum, Kirsten Van Hoorde, Jigar Desai, Lorenzo Acciarri, Margot J. Pont, Anna van Muyden, Omotayo Fasan, Joost S.P. Vermaat, Sébastien Anguille